Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

If you’re on the fence about investing in Gilead Sciences, Inc., BeiGene or Ltd. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

Dec. 30, 2024 — A new species of black, slender moray eel has chosen the road less traveled, thriving in dim and muddy river mouths, unlike most of its marine ... Six New Tree Species Named: 3 ...

Humanities & Social Sciences Communications is a fully open-access, online journal publishing peer-reviewed research from across—and between—all areas of the humanities, behavioral and social ...